USFDA completes inspection at Dr Reddy's Labs Bachupally RnD centre

Hyderabad: In a recent BSE filing, Dr Reddy's Labs has informed that the United States Food & Drug Administration (USFDA) has completed a routine Good Manufacturing Practice (GMP) inspection at the Company's R&D centre (Integrated Product Development Organisation or IPDO) in Bachupally, Hyderabad with zero observations.

The inspection was conducted from 16th September to 20th September, 2024.

Read also: Dr Sridevi Khambhampaty appointed as CEO of Shilpa Biologicals

Medical Dialogues team had earlier reported that Dr Reddy's Labs had received the Establishment Inspection Report (EIR) from the USFDA for the formulations manufacturing facility (FTO-3) in Bachupally, Hyderabad.

Read also: Dr Reddy's Labs gets USFDA EIR for Bachupally facility

Established in 1984, Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. The Company offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy's Labs major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe